|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2010-8-20
|
|
pubmed:abstractText |
Recently a class of compounds known as triple reuptake inhibitors has emerged as a new strategy for the treatment of depression. These compounds work by simultaneously inhibiting the synaptic reuptake of serotonin, norepinephrine and dopamine. In this Letter we describe the optimization of a novel series of 2-substituted N-aryl piperazine based triple reuptake inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3941-5
|
|
pubmed:meshHeading |
pubmed-meshheading:20570146-Animals,
pubmed-meshheading:20570146-Antidepressive Agents,
pubmed-meshheading:20570146-Depression,
pubmed-meshheading:20570146-Dopamine,
pubmed-meshheading:20570146-Dose-Response Relationship, Drug,
pubmed-meshheading:20570146-Mice,
pubmed-meshheading:20570146-Molecular Structure,
pubmed-meshheading:20570146-Neurotransmitter Uptake Inhibitors,
pubmed-meshheading:20570146-Norepinephrine,
pubmed-meshheading:20570146-Piperazines,
pubmed-meshheading:20570146-Serotonin,
pubmed-meshheading:20570146-Stereoisomerism,
pubmed-meshheading:20570146-Structure-Activity Relationship,
pubmed-meshheading:20570146-Synapses
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Roche Palo Alto LLC, CA 94304, USA. david.carter5@comcast.net
|
|
pubmed:publicationType |
Journal Article
|
